Agilent and Akoya have partnered to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis. Credit: National Cancer Institute / Unsplash.

Agilent Technologies and Akoya Biosciences have collaborated to develop multiplex-immunohistochemistry diagnostic products for tissue analysis.

The companies have also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the partnership, Agilent will integrate its Dako Omnis auto-staining instrument with Akoya’s imaging platform, PhenoImager HT, for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays.

This integration will create a single end-to-end commercial workflow that will include reagents, staining, imaging and analysis.

Together Agilent and Akoya will develop chromogenic and immunofluorescent multiplex assays, which will include spatial analysis for companies that develop precision therapeutics for cancer.

See Also:

The new assays will help researchers and medical professionals meet patient selection requirements for new therapeutics as well as quickly advance their discoveries to clinical testing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using multiplex imaging, spatial phenotyping provides the advantages of single-cell analysis while allowing the preservation of the spatial relationships between cells.

Agilent Diagnostic and Genomics Group president Sam Raha said: “We are delighted to be partnering with Akoya to create industry-leading products and services for multiplex chromogenic and immunofluorescence tissue assays.

“This partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to our joint customers in the clinical research market to meet the needs of future clinical diagnostics.”

The company stated that the collaboration aims to develop an end-to-end multiplex solution for biomarker clinical research that is enabled by digital pathology and provides capabilities across the pharma value chain.

It will combine Agilent’s pharma partners network, expertise in companion diagnostic and immunohistochemistry (IHC) workflow, and Dako Omnis instrument install base with Akoya’s spatial analysis expertise, Clinical Laboratory Improvement Amendments (CLIA) lab capabilities and imagers install base.

Under a separate agreement, Akoya Biosciences will also be responsible for distributing and reselling Agilent’s Dako Omnis instrument as a part of the multiplex solution.

Akoya Biosciences CEO Brian McKelligon said: “Multiplex tissue analysis has the potential to transform the field of cancer therapeutics and usher in a new era of precision pathology.

“This partnership and the combined strength of both organisations will catalyse the development and deployment of multiplex tissue-based biomarkers for the benefit of our biopharma and CRO partners and, ultimately, patients.”